Abingworth to invest over 50% of $375m life sciences fund in pharma
This article was originally published in Scrip
Executive Summary
International investment group Abingworth has closed its tenth life sciences fund worth £225m ($375m), which will be used to invest broadly across the life sciences industry in Europe and the US, with the majority of funds expected to go to pharmaceutical projects.